Product
Supplier
Encyclopedia
Inquiry
Home > Encyclopedia > Epalrestat

Epalrestat

pharmaceutical raw materials
Epalrestat structure

Epalrestat 

structure
  • CAS No:

    82159-09-9

  • Formula:

    C15H13NO3S2

  • Chemical Name:

    Epalrestat

  • Synonyms:

    3-Thiazolidineacetic acid,5-[(2E)-2-methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-,(5Z)-;3-Thiazolidineacetic acid,5-(2-methyl-3-phenyl-2-propenylidene)-4-oxo-2-thioxo-,(Z,E)-;3-Thiazolidineacetic acid,5-[(2E)-2-methyl-3-phenyl-2-propenylidene]-4-oxo-2-thioxo-,(5Z)-;(5Z)-5-[(2E)-2-Methyl-3-phenyl-2-propen-1-ylidene]-4-oxo-2-thioxo-3-thiazolidineacetic acid;ONO 2235;Epalrestat;Kinedak;Sorbistat;Eabeth;2-[(Z)-5-((E)-2-Methyl-3-phenylallylidene)-4-oxo-2-thioxothiazolidin-3-yl]acetic acid;125654-73-1

  • Categories:

    Active Pharmaceutical Ingredients  >  Hormones and the Endocrine System

Description

Epalrestat is an aldose reductase inhibitor for the treatment of diabetic neuropathy.Target: Aldose ReductaseEpalrestat may affect or delay progression of the underlying disease process. Data from six clinical trials were evaluated, and it was determined that epalrestat 50 mg 3 times/day may improve motor and sensory nerve conduction velocity and subjective neuropathy symptoms as compared with baseline and placebo. Epalrestat may serve as a new therapeutic option to prevent or slow the p


Epalrestat is a monocarboxylic acid that is 1,3-thiazolidine which is substituted on the nitrogen by a carboxymethyl group, at positions 2 and 4 by thioxo and oxo groups, respectively, and at position 5 by a 2-methyl-3-phenylprop-2-en-1-ylidene group. It is an inhibitor of aldose reductase (which catalyses the conversion of glucose to sorbitol) and is used for the treatment of some diabetic complications, including neuropathy. It has a role as an EC 1.1.1.21 (aldehyde reductase) inhibitor. It is a member of thiazolidines and a monocarboxylic acid.|Epalrestat is under investigation in clinical trial NCT03244358 (Evaluation of Epalrestat in Metastatic Triple-negative Breast Cancer).|Epalrestat is an orally available, a non-competitive, reversible inhibitor of aldose reductase (AR), with potential antineoplastic, antioxidant, and anti-inflammatory activities. Upon oral administration, epalrestat non-competitively binds to AR, a polyol pathway enzyme that catalyzes reactive oxygen species (ROS)-initiated lipid peroxidation-generated lipid aldehydes and their glutathione conjugates, which have been implicated in the activation of transcription factors such as nuclear factor kappa-light-chain-enhancer of activated B cells (NF-kappa B) and activator protein-1 (AP-1), which control the transcription of many inflammatory cytokines. Increased inflammatory cytokines and growth factors promote cell proliferation, a primary feature in the tumorigenesis process. AR is overexpressed in several oxidative stress- and inflammation-related conditions, including cancer.

Epalrestat Basic Attributes

319.4

319.40

1312995-182-4

424DV0807X

DTXSID1046479

C72762

Characteristics

115

3.8

yellow to orange

1.4±0.1 g/cm3

210-217 °C

516.8°C at 760 mmHg

266.4±32.9 °C

1.706

DMSO: soluble5mg/mL, clear (warmed)

-20°C Freezer

Oral-rat LD50: 5.3 mg/kg; Intravenous-Mouse LD50: 0.255 mg/kg

Combustible, fires emit nitrogen oxides, sulfur oxides pungently stimulate smoke

Safety Information

II

6.1

2811

3

XJ5131855

Ventilated, low temperature and dry; stored separately from food materials in warehouse

P261, P264, P270, P271, P280, P301+P310, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, P501

H300

|Danger|H300 (50%): Fatal if swallowed [Danger Acute toxicity, oral]|P261, P264, P270, P271, P280, P301+P310, P302+P352, P304+P340, P305+P351+P338, P312, P321, P330, P332+P313, P337+P313, P362, P403+P233, P405, and P501|Aggregated GHS information provided by 2 companies from 2 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.

Toxicity

most toxic

Drug Information

Compounds or agents that combine with an enzyme in such a manner as to prevent the normal substrate-enzyme combination and the catalytic reaction. (See all compounds classified as Enzyme Inhibitors.)

3-carboxymethyl-5-(methyl-3-phenylpropenylidene)rhodanine

Epalrestat Use and Manufacturing

An aldose reductase inhibitor. It is used in treatment of diabetic neuropathy.

Computed Properties

Molecular Weight:319.4
XLogP3:3.8
Hydrogen Bond Donor Count:1
Hydrogen Bond Acceptor Count:5
Rotatable Bond Count:4
Exact Mass:319.03368562
Monoisotopic Mass:319.03368562
Topological Polar Surface Area:115
Heavy Atom Count:21
Complexity:519
Defined Bond Stereocenter Count:2
Covalently-Bonded Unit Count:1
Compound Is Canonicalized:Yes

Drug Function and Efficacy

Extract from the above information

This ingredient has been used in drugs with the following functions (note: it does not mean that the ingredient itself has the following health functions)

Related Drugs

Registered Holders

Recommended Suppliers of Epalrestat

Scan the QR Code to Share

Feedback & Suggestions
Send Message

Thank you for your feedback. If you require further assistance, please contact us by email at info@echemi.com or call us at +86-532-55729510.